IRIS
BERGANTINI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.442
NA - Nord America 5.468
AS - Asia 1.231
SA - Sud America 365
AF - Africa 85
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 6
Totale 15.613
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.415
IT - Italia 2.561
IE - Irlanda 1.499
GB - Regno Unito 1.320
RU - Federazione Russa 682
SE - Svezia 621
DE - Germania 533
SG - Singapore 497
FR - Francia 394
BR - Brasile 318
FI - Finlandia 302
CN - Cina 281
UA - Ucraina 114
NL - Olanda 104
ES - Italia 93
IN - India 92
VN - Vietnam 73
HK - Hong Kong 64
CZ - Repubblica Ceca 60
CI - Costa d'Avorio 56
CA - Canada 38
AT - Austria 33
IR - Iran 28
TR - Turchia 28
JP - Giappone 20
CH - Svizzera 18
BE - Belgio 16
PH - Filippine 16
AU - Australia 15
AR - Argentina 12
BD - Bangladesh 12
PK - Pakistan 12
AE - Emirati Arabi Uniti 11
PL - Polonia 11
UZ - Uzbekistan 11
EC - Ecuador 10
MA - Marocco 10
PE - Perù 10
BG - Bulgaria 9
EE - Estonia 9
AZ - Azerbaigian 8
IL - Israele 8
LV - Lettonia 8
PT - Portogallo 8
CL - Cile 7
GE - Georgia 7
KR - Corea 7
MX - Messico 7
DK - Danimarca 6
EU - Europa 6
HU - Ungheria 6
KG - Kirghizistan 6
KZ - Kazakistan 6
LK - Sri Lanka 6
ZA - Sudafrica 6
LT - Lituania 5
PA - Panama 5
RO - Romania 5
CY - Cipro 4
EG - Egitto 4
HR - Croazia 4
JO - Giordania 4
LA - Repubblica Popolare Democratica del Laos 4
MK - Macedonia 4
NG - Nigeria 4
NO - Norvegia 4
AM - Armenia 3
CO - Colombia 3
GR - Grecia 3
ID - Indonesia 3
IQ - Iraq 3
LB - Libano 3
SA - Arabia Saudita 3
JM - Giamaica 2
LU - Lussemburgo 2
MY - Malesia 2
OM - Oman 2
PY - Paraguay 2
QA - Qatar 2
RS - Serbia 2
TN - Tunisia 2
TW - Taiwan 2
AL - Albania 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
DZ - Algeria 1
GA - Gabon 1
IM - Isola di Man 1
IS - Islanda 1
MD - Moldavia 1
MM - Myanmar 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SI - Slovenia 1
SN - Senegal 1
TH - Thailandia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 15.613
Salva come PNG Salva come JPEG
Città #
Dublin 1.472
Southend 1.187
Santa Clara 723
Chandler 623
Fairfield 617
Siena 474
Ashburn 412
Lastra a Signa 340
Singapore 274
Helsinki 262
Milan 246
Woodbridge 230
Wilmington 224
Houston 213
Seattle 206
Princeton 186
Munich 184
Cambridge 179
Florence 150
New York 139
Ann Arbor 126
Rome 85
Los Angeles 76
Shanghai 75
Moscow 70
Beijing 65
Dong Ket 64
Jacksonville 64
Fremont 63
Lauterbourg 62
Málaga 59
San Mateo 59
Abidjan 56
Nuremberg 53
Düsseldorf 52
Hong Kong 50
San Diego 50
Portsmouth 48
Boardman 47
Dearborn 47
Brno 40
Brescia 29
São Paulo 29
Washington 29
Dallas 27
London 27
Frankfurt am Main 26
Gavirate 24
Chicago 23
Lappeenranta 23
Padova 23
Agliana 19
Naples 18
Newark 18
Tarazona 17
Brussels 16
Livorno 16
Toronto 16
Vienna 16
Olomouc 15
Tokyo 14
Cagliari 13
Hyderabad 13
Nanjing 12
The Dalles 12
Zanjan 12
Zurich 12
Aachen 11
Amsterdam 11
Bologna 11
Council Bluffs 11
Chianciano Terme 10
Comun Nuovo 10
Guangzhou 10
Pasig 10
Pune 10
Redwood City 10
Tashkent 10
Bangalore 9
Belo Horizonte 9
Catania 9
Dhaka 9
Espoo 9
Lima 9
Norwalk 9
Paris 9
Pisa 9
Prato 9
San Francisco 9
Sofia 9
Baku 8
Bergamo 8
Carrara 8
Grosseto 8
Izmir 8
Nanchang 8
Riga 8
Rio de Janeiro 8
Bari 7
Hefei 7
Totale 10.451
Salva come PNG Salva come JPEG
Nome #
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 321
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 246
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 228
Genetic mechanisms of critical illness in COVID-19 227
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 216
Peripheral biomarkers' panel for severe COVID-19 patients 211
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 209
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 205
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 193
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 188
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients 187
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 180
Pathogen-sugar interactions revealed by universal saturation transfer analysis 175
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 175
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 175
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 174
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 171
NK and NKT-like cells in granulomatous and fibrotic lung diseases 160
Mapping the human genetic architecture of COVID-19 160
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 159
Prognostic bioindicators in severe COVID-19 patients 159
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 153
A first update on mapping the human genetic architecture of COVID-19 151
Serum amyloid A in patients with idiopathic pulmonary fibrosis 147
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 145
Serial KL-6 measurements in COVID-19 patients 143
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 143
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 136
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 134
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 133
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 132
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 130
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 129
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 128
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 127
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 127
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 127
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 127
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 126
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 124
Serum amyloid A: A potential biomarker of lung disorders 122
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 122
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 122
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 122
An explainable model of host genetic interactions linked to COVID-19 severity 120
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 120
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 119
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 118
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 117
Effects of rituximab therapy on B cell differentiation and depletion 116
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 115
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 115
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 115
WES profiling of COVID-19 113
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 112
null 111
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 111
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 109
Serum KL-6 levels in Pulmonary Langerhans' Cell Histiocytosis 109
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 108
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? 107
Interstitial lung disease associated with psoriatic arthritis: a new disease entity? 107
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 106
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 105
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 104
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 103
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 103
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 102
Immunologic responses to antifibrotic treatment in IPF patients 102
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 100
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 100
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 99
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 98
Clinical and molecular characterization of COVID-19 hospitalized patients 97
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy 96
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 96
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 95
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 95
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 94
Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report 94
Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases 93
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 90
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review 90
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 89
Clinical phenotyping in sarcoidosis management 86
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 85
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 85
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists 85
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 85
KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach 84
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 84
Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility 82
Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone 82
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab 81
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 79
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis 78
Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis 78
Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): A New Phenotype or a Fortuitous Overlap? Scoping Review and Case Series 78
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 77
Alteration of Immune-checkpoint after specific stimulation with CMV antigens in pre-LTx patients 75
Totale 12.666
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.972
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.972
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020142 0 0 0 0 0 0 0 0 0 0 51 91
2020/20212.166 64 100 101 271 185 246 160 256 217 147 217 202
2021/20222.306 175 268 201 159 113 100 95 104 101 295 262 433
2022/20232.707 175 294 334 266 155 479 283 236 183 117 111 74
2023/20243.095 119 95 316 163 158 661 869 147 43 103 119 302
2024/20255.032 603 268 757 395 788 424 381 419 535 350 112 0
Totale 16.367